Published in AIDS on August 24, 2009
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med (2010) 8.72
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev (2011) 3.28
Understanding latent tuberculosis: a moving target. J Immunol (2010) 2.95
Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS (2010) 2.90
Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected Tanzanian adults initiating antiretroviral therapy. J Infect Dis (2012) 2.87
Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis (2011) 2.72
Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis (2010) 2.60
Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One (2012) 2.53
Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One (2012) 2.39
Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med (2009) 2.20
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr (2011) 2.16
Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS (2010) 2.14
Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One (2010) 2.14
HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun (2011) 2.03
Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol (2011) 1.98
Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS (2010) 1.83
Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis (2011) 1.76
Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One (2010) 1.72
Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr (2011) 1.69
HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med (2009) 1.54
Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc (2010) 1.51
Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A (2010) 1.48
Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr (2011) 1.42
Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med (2010) 1.42
Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis (2012) 1.37
Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One (2013) 1.35
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health (2010) 1.30
Impact of human immunodeficiency virus and CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South Africa. Int J Tuberc Lung Dis (2013) 1.28
Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis. Front Immunol (2014) 1.28
Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2012) 1.26
Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol (2010) 1.25
Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. Pulm Med (2012) 1.24
Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther (2011) 1.20
Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list'. Int J Tuberc Lung Dis (2013) 1.12
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis (2011) 1.11
Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention. J Acquir Immune Defic Syndr (2013) 1.11
Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol (2010) 1.09
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med (2012) 1.09
Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc Am Thorac Soc (2011) 1.07
Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria. J Acquir Immune Defic Syndr (2014) 1.03
Population-based CD4 counts in a rural area in South Africa with high HIV prevalence and high antiretroviral treatment coverage. PLoS One (2013) 1.02
Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008. PLoS One (2013) 1.02
CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res Hum Retroviruses (2012) 1.02
The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South Africa. Open Forum Infect Dis (2014) 1.00
Frailty in HIV-infected adults in South Africa. J Acquir Immune Defic Syndr (2013) 0.99
Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012. PLoS One (2014) 0.97
Retreatment tuberculosis in a South African community: the role of re-infection, HIV and antiretroviral treatment. Int J Tuberc Lung Dis (2012) 0.97
HIV-1 and the immune response to TB. Future Virol (2013) 0.97
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS One (2014) 0.95
Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. Open Forum Infect Dis (2014) 0.95
Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One (2014) 0.95
Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study. AIDS Res Hum Retroviruses (2013) 0.94
Timing of antiretroviral therapy and regimen for HIV-infected patients with tuberculosis: the effect of revised HIV guidelines in Malawi. BMC Public Health (2014) 0.94
Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART. PLoS One (2012) 0.94
Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One (2012) 0.93
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis. Clin Dev Immunol (2012) 0.93
Recent developments in the epidemiology and management of tuberculosis - new solutions to old problems? Infect Drug Resist (2012) 0.92
Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge. Curr HIV/AIDS Rep (2015) 0.89
Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects. PLoS One (2013) 0.88
CD4-CD8-αβ and γδ T cells display inflammatory and regulatory potentials during human tuberculosis. PLoS One (2012) 0.87
Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis (2011) 0.87
Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count. Clin Infect Dis (2010) 0.87
Control of T cell antigen reactivity via programmed TCR downregulation. Nat Immunol (2016) 0.87
Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. Open AIDS J (2009) 0.85
Temporal trends in TB notification rates during ART scale-up in Cape Town: an ecological analysis. J Int AIDS Soc (2015) 0.85
Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis. Curr HIV Res (2011) 0.84
Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One (2010) 0.84
Tuberculosis Case Finding in HIV-Infected Pregnant Women in Kenya Reveals Poor Performance of Symptom Screening and Rapid Diagnostic Tests. J Acquir Immune Defic Syndr (2016) 0.83
Impaired M. tuberculosis Antigen-Specific IFN-γ Response without IL-17 Enhancement in Patients with Severe Cavitary Pulmonary Tuberculosis. PLoS One (2015) 0.83
The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS One (2012) 0.83
Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PLoS One (2013) 0.83
Assessing the impact of prevalent tuberculosis on mortality among antiretroviral treatment initiators: accurate tuberculosis diagnosis is essential. AIDS (2012) 0.83
Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res (2011) 0.83
Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Ther (2009) 0.83
Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS (2015) 0.82
Early versus Delayed Antiretroviral Therapy for HIV and Tuberculosis Co-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 0.82
Multifaceted Impact of Host C-C Chemokine CCL2 in the Immuno-Pathogenesis of HIV-1/M. tuberculosis Co-Infection. Front Immunol (2013) 0.82
Variation of Mycobacterium tuberculosis antigen-specific IFN-γ and IL-17 responses in healthy tuberculin skin test (TST)-positive human subjects. PLoS One (2012) 0.81
Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen. Clin Infect Dis (2011) 0.81
Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One (2015) 0.79
Reducing the burden of tuberculosis presenting during the initial months of antiretroviral therapy in resource-limited settings. Clin Infect Dis (2010) 0.79
Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr (2015) 0.79
The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy. BMC Infect Dis (2016) 0.79
The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax (2017) 0.78
Tuberculosis and HIV coinfection in Europe: looking at one reality from two angles. AIDS (2016) 0.78
Serological diagnostic assays for HIV-associated tuberculosis in sub-Saharan Africa? Clin Vaccine Immunol (2014) 0.78
The impact of HIV status and antiretroviral treatment on TB treatment outcomes of new tuberculosis patients attending co-located TB and ART services in South Africa: a retrospective cohort study. BMC Infect Dis (2015) 0.78
Combined antiretroviral and anti-tuberculosis drug resistance following incarceration. South Afr J HIV Med (2013) 0.77
Remote sensing of HIV care programmes using centrally collected laboratory results: can we monitor ART programme effectiveness? S Afr Med J (2012) 0.77
Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study. BMC Med (2016) 0.77
Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host Microbe (2017) 0.76
Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis (2016) 0.76
Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria. Open Forum Infect Dis (2015) 0.76
Timely HIV diagnosis and HIV/TB comanagement among California patients in 2008. Public Health Rep (2014) 0.75
Relationship Between HIV Coinfection, Interleukin 10 Production, and Mycobacterium tuberculosis in Human Lymph Node Granulomas. J Infect Dis (2016) 0.75
Interleukin 1-beta (IL-1β) production by innate cells following TLR stimulation correlates with TB recurrence in ART-treated HIV infected patients. J Acquir Immune Defic Syndr (2016) 0.75
Antiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methods. PLoS One (2011) 0.75
Tuberculosis diagnostics: Challenges and opportunities. Lung India (2012) 0.75
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS (2005) 6.83
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. April 2002. IAPAC Mon (2002) 6.33
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J (2006) 6.29
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS (2007) 4.52
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med (2005) 3.90
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis (2000) 3.37
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS (2005) 2.96
Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med (2007) 2.88
Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science (2003) 2.83
Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis (2007) 2.79
Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis (2006) 2.72
Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS (2006) 2.69
CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis (2006) 2.68
Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med (2008) 2.63
Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis (2002) 2.30
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS (2005) 2.28
Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis (2006) 1.89
Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS (2000) 1.82
Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med (2000) 1.55
Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS (2009) 1.49
Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis (2007) 1.49
Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS, 22 July 2005. AIDS (2005) 1.45
Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect (2003) 1.41
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
The genome of the mesopolyploid crop species Brassica rapa. Nat Genet (2011) 8.23
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis (2011) 7.23
Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS (2005) 6.83
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J (2006) 6.29
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68
Averting biodiversity collapse in tropical forest protected areas. Nature (2012) 4.46
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
"Life is still going on": reproductive intentions among HIV-positive women and men in South Africa. Soc Sci Med (2007) 4.14
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res (2008) 3.45
Draft genome sequence of chickpea (Cicer arietinum) provides a resource for trait improvement. Nat Biotechnol (2013) 3.41
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31
Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav (2009) 3.29
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther (2007) 3.27
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14
Redundancy based detection of sequence polymorphisms in expressed sequence tag data using autoSNP. Bioinformatics (2003) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health (2009) 2.99
Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J (2009) 2.97
Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS (2008) 2.96
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92
Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS (2010) 2.90
When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (2006) 2.85
Screening for serious mental illness in the general population with the K6 screening scale: results from the WHO World Mental Health (WMH) survey initiative. Int J Methods Psychiatr Res (2010) 2.81
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS (2004) 2.78
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis (2011) 2.72
Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.72